208 related articles for article (PubMed ID: 34312774)
1. Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial.
Letourneau J; Juarez-Hernandez F; Wald K; Ribeiro S; Wang A; McCulloch CE; Mok-Lin E; Dolezal M; Chien AJ; Cedars MI; Rosen M
J Assist Reprod Genet; 2021 Sep; 38(9):2455-2463. PubMed ID: 34312774
[TBL] [Abstract][Full Text] [Related]
2. Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients.
Shulman Y; Almog B; Kalma Y; Fouks Y; Azem F; Cohen Y
J Assist Reprod Genet; 2021 Mar; 38(3):743-750. PubMed ID: 33409757
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
4. The impact of letrozole administration on oocyte morphology in breast cancer patients undergoing fertility preservation.
Bercaire LMN; Cavagna M; Donadio NF; Rocha AR; Portela R; Alves VR; Santos TBB; Cavagna F; Dzik A; Gebrim LH; Nahas EAP
JBRA Assist Reprod; 2020 Jul; 24(3):257-264. PubMed ID: 32293820
[TBL] [Abstract][Full Text] [Related]
5. Response to ovarian stimulation in patients facing gonadotoxic therapy.
Johnson LN; Dillon KE; Sammel MD; Efymow BL; Mainigi MA; Dokras A; Gracia CR
Reprod Biomed Online; 2013 Apr; 26(4):337-44. PubMed ID: 23415997
[TBL] [Abstract][Full Text] [Related]
6. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients.
Turan V; Bedoschi G; Moy F; Oktay K
Fertil Steril; 2013 Dec; 100(6):1681-5.e1. PubMed ID: 24055050
[TBL] [Abstract][Full Text] [Related]
7. Fertility preservation in women with breast cancer.
Rodriguez-Wallberg KA; Oktay K
Clin Obstet Gynecol; 2010 Dec; 53(4):753-62. PubMed ID: 21048442
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.
Dahhan T; Balkenende EME; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; van Golde RJT; Schipper I; Louwé LA; Cantineau AEP; Smeenk JMJ; de Bruin JP; Reddy N; Kopeika Y; van der Veen F; van Wely M; Linn SC; Goddijn M
Contemp Clin Trials; 2017 Oct; 61():96-100. PubMed ID: 28710053
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†.
Pereira N; Hancock K; Cordeiro CN; Lekovich JP; Schattman GL; Rosenwaks Z
Gynecol Endocrinol; 2016 Oct; 32(10):823-826. PubMed ID: 27114051
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
[TBL] [Abstract][Full Text] [Related]
11. Effect of letrozole added to gonadotropins in controlled ovarian stimulation protocols on the yield and maturity of retrieved oocytes.
Ben-Haroush A; Wertheimer A; Klochendler E; Sapir O; Shufaro Y; Oron G
Gynecol Endocrinol; 2019 Apr; 35(4):324-327. PubMed ID: 30596311
[TBL] [Abstract][Full Text] [Related]
12. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
[TBL] [Abstract][Full Text] [Related]
13. Hormone concentrations of dominant follicles in the TALES randomized controlled trial comparing letrozole with tamoxifen.
Wang A; Letourneau JM; Juarez-Hernandez F; Abel MK; Mok-Lin E; Rosen MP
J Assist Reprod Genet; 2022 Nov; 39(11):2617-2624. PubMed ID: 36192617
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction.
Dahhan T; Balkenende E; van Wely M; Linn S; Goddijn M
Cochrane Database Syst Rev; 2013 Nov; (11):CD010240. PubMed ID: 24213953
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
[TBL] [Abstract][Full Text] [Related]
16. Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes.
Turan V; Bedoschi G; Emirdar V; Moy F; Oktay K
Reprod Sci; 2018 Jan; 25(1):26-32. PubMed ID: 28874104
[TBL] [Abstract][Full Text] [Related]
17. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers.
Goldrat O; Van Den Steen G; Gonzalez-Merino E; Dechène J; Gervy C; Delbaere A; Devreker F; De Maertelaer V; Demeestere I
Reprod Biol Endocrinol; 2019 Jan; 17(1):3. PubMed ID: 30606204
[TBL] [Abstract][Full Text] [Related]
18. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.
Oktay K; Buyuk E; Libertella N; Akar M; Rosenwaks Z
J Clin Oncol; 2005 Jul; 23(19):4347-53. PubMed ID: 15824416
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
20. Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response.
Volodarsky-Perel A; Cohen Y; Arab S; Son WY; Suarthana E; Dahan MH; Tulandi T; Buckett W
Hum Reprod; 2019 Mar; 34(3):530-538. PubMed ID: 30689898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
